AbbVie Allocates $380M to Enhance Illinois Manufacturing for Neuroscience and Obesity Treatments

AbbVie announced on Monday a significant investment of $380 million aimed at constructing two new active pharmaceutical ingredient (API) manufacturing facilities at its Illinois campus. This expansion is designed to enhance the company’s domestic production capacity for its neuroscience and obesity medications.

This investment is part of AbbVie’s larger strategy to increase domestic manufacturing capabilities. In recent years, pharmaceutical companies have been under pressure to bolster their U.S. manufacturing capacity and inventory, particularly in light of the Trump administration’s substantial tariffs on imported pharmaceuticals.

In October, the U.S. government imposed a 100% tariff on branded drugs, although it specified that this would only affect producers who had not yet commenced construction on U.S. manufacturing plants.

AbbVie plans to begin construction of the new facility in North Chicago, Illinois, in the spring of 2026, with both facilities expected to be fully operational by 2029. The new sites will incorporate advanced manufacturing technologies and artificial intelligence to facilitate the production of future pipeline medicines, according to the company.

The production of active pharmaceutical ingredients is one of the most intricate processes in pharmaceutical manufacturing. AbbVie emphasized the complexity involved in creating the active chemical components of drugs.

As part of this expansion, AbbVie intends to hire approximately 300 individuals in North Chicago. The new roles will include engineers, scientists, manufacturing operators, and lab technicians, reflecting the company’s commitment to local job creation.

Earlier this year, AbbVie pledged $100 billion over the next decade for U.S.-based research and development. This includes a prior investment of $195 million to expand API production at the same North Chicago site, aimed at enhancing production for immunology, oncology, and neuroscience drugs.

Currently, AbbVie operates 11 manufacturing sites across the United States. The company is also in discussions with several U.S. states regarding potential projects and anticipates announcing additional investments in 2026.

(Reporting by Mahatole in Bengaluru; Editing by Maju Samuel)

Topics
Illinois
Manufacturing

AbbVie announced on Monday a significant investment of $380 million aimed at constructing two new active pharmaceutical ingredient (API) manufacturing facilities at its Illinois campus. This expansion is designed to enhance the company’s domestic production capacity for its neuroscience and obesity medications.

This investment is part of AbbVie’s larger strategy to increase domestic manufacturing capabilities. In recent years, pharmaceutical companies have been under pressure to bolster their U.S. manufacturing capacity and inventory, particularly in light of the Trump administration’s substantial tariffs on imported pharmaceuticals.

In October, the U.S. government imposed a 100% tariff on branded drugs, although it specified that this would only affect producers who had not yet commenced construction on U.S. manufacturing plants.

AbbVie plans to begin construction of the new facility in North Chicago, Illinois, in the spring of 2026, with both facilities expected to be fully operational by 2029. The new sites will incorporate advanced manufacturing technologies and artificial intelligence to facilitate the production of future pipeline medicines, according to the company.

The production of active pharmaceutical ingredients is one of the most intricate processes in pharmaceutical manufacturing. AbbVie emphasized the complexity involved in creating the active chemical components of drugs.

As part of this expansion, AbbVie intends to hire approximately 300 individuals in North Chicago. The new roles will include engineers, scientists, manufacturing operators, and lab technicians, reflecting the company’s commitment to local job creation.

Earlier this year, AbbVie pledged $100 billion over the next decade for U.S.-based research and development. This includes a prior investment of $195 million to expand API production at the same North Chicago site, aimed at enhancing production for immunology, oncology, and neuroscience drugs.

Currently, AbbVie operates 11 manufacturing sites across the United States. The company is also in discussions with several U.S. states regarding potential projects and anticipates announcing additional investments in 2026.

(Reporting by Mahatole in Bengaluru; Editing by Maju Samuel)

Topics
Illinois
Manufacturing